Colorectal Cancer Clinical Trials

If you are an interested patient, researcher or sponsor, please feel free to call us at (845) 483-6825 or email

Open to Enrollment 


Closed to Enrollment

Study Identifier: ALLIANCE A021502 (ATOMIC)

Principal Investigator: Radhika Rachamalla, MD
Study Title:Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Study Summary: This randomized phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.

Study Identifier: N1048/PROSPECT
Principal Investigator: James Nitzkorski, MD
Study Title: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery

Study Summary: The purpose of the N1048 study is to evaluate how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery. The drugs in the chemotherapy regimen are all FDA approved and have been used routinely since 2002 to treat patients with advanced colorectal cancer. It is not yet known whether chemotherapy alone is more effective than chemotherapy plus radiation therapy in treating rectal cancer.